Literature DB >> 21732249

Fragment-based lead discovery: challenges and opportunities.

Chaohong Sun1, Andrew M Petros, Philip J Hajduk.   

Abstract

Fragment-based lead discovery has undergone remarkable changes over the last 15 years. During this time, the pharmaceutical industry has changed dramatically as well, and continued evolution of the industry is assured. These changes present many challenges but also several opportunities for executing fragment-based drug design. This article will explore some of the more significant changes in the industry and how they may affect future discovery efforts related to fragment-based initiatives.

Mesh:

Substances:

Year:  2011        PMID: 21732249     DOI: 10.1007/s10822-011-9451-z

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  25 in total

Review 1.  Why is big Pharma getting out of antibacterial drug discovery?

Authors:  Steven J Projan
Journal:  Curr Opin Microbiol       Date:  2003-10       Impact factor: 7.934

Review 2.  Structure-based drug discovery and protein targets in the CNS.

Authors:  Roderick E Hubbard
Journal:  Neuropharmacology       Date:  2010-07-29       Impact factor: 5.250

Review 3.  Target-based drug discovery: is something wrong?

Authors:  Frank Sams-Dodd
Journal:  Drug Discov Today       Date:  2005-01-15       Impact factor: 7.851

Review 4.  Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology.

Authors:  Jan van der Greef; Robert N McBurney
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

Review 5.  Chemoproteomics-driven drug discovery: addressing high attrition rates.

Authors:  Steven E Hall
Journal:  Drug Discov Today       Date:  2006-06       Impact factor: 7.851

Review 6.  Fragment-based lead discovery: a chemical update.

Authors:  Daniel A Erlanson
Journal:  Curr Opin Biotechnol       Date:  2006-11-03       Impact factor: 9.740

Review 7.  A network view of disease and compound screening.

Authors:  Eric E Schadt; Stephen H Friend; David A Shaywitz
Journal:  Nat Rev Drug Discov       Date:  2009-04       Impact factor: 84.694

8.  Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase.

Authors:  Alvin W Hung; H Leonardo Silvestre; Shijun Wen; Alessio Ciulli; Tom L Blundell; Chris Abell
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

Review 9.  The impact of GPCR structures on pharmacology and structure-based drug design.

Authors:  Miles Congreve; Fiona Marshall
Journal:  Br J Pharmacol       Date:  2009-11-13       Impact factor: 8.739

10.  Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.

Authors:  Jeffrey R Huth; Chang Park; Andrew M Petros; Aaron R Kunzer; Michael D Wendt; Xilu Wang; Christopher L Lynch; Jamey C Mack; Kerry M Swift; Russell A Judge; Jun Chen; Paul L Richardson; Sha Jin; Stephen K Tahir; Edward D Matayoshi; Sarah A Dorwin; Uri S Ladror; Jean M Severin; Karl A Walter; Diane M Bartley; Stephen W Fesik; Steven W Elmore; Philip J Hajduk
Journal:  Chem Biol Drug Des       Date:  2007-07       Impact factor: 2.817

View more
  7 in total

Review 1.  Antibody-enabled small-molecule drug discovery.

Authors:  Alastair D G Lawson
Journal:  Nat Rev Drug Discov       Date:  2012-06-29       Impact factor: 84.694

Review 2.  Oncogenic protein interfaces: small molecules, big challenges.

Authors:  Tracy L Nero; Craig J Morton; Jessica K Holien; Jerome Wielens; Michael W Parker
Journal:  Nat Rev Cancer       Date:  2014-03-13       Impact factor: 60.716

3.  Missing fragments: detecting cooperative binding in fragment-based drug design.

Authors:  Pramod C Nair; Alpeshkumar K Malde; Nyssa Drinkwater; Alan E Mark
Journal:  ACS Med Chem Lett       Date:  2012-02-14       Impact factor: 4.345

4.  Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5.

Authors:  Yuemin Bian; Zhiwei Feng; Peng Yang; Xiang-Qun Xie
Journal:  AAPS J       Date:  2017-05-30       Impact factor: 4.009

5.  Fragment screening of cyclin G-associated kinase by weak affinity chromatography.

Authors:  Elinor Meiby; Stefan Knapp; Jonathan M Elkins; Sten Ohlson
Journal:  Anal Bioanal Chem       Date:  2012-08-24       Impact factor: 4.142

6.  Putative histidine kinase inhibitors with antibacterial effect against multi-drug resistant clinical isolates identified by in vitro and in silico screens.

Authors:  Nadya Velikova; Simone Fulle; Ana Sousa Manso; Milena Mechkarska; Paul Finn; J Michael Conlon; Marco Rinaldo Oggioni; Jerry M Wells; Alberto Marina
Journal:  Sci Rep       Date:  2016-05-13       Impact factor: 4.379

Review 7.  In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs.

Authors:  Zarko Gagic; Dusan Ruzic; Nemanja Djokovic; Teodora Djikic; Katarina Nikolic
Journal:  Front Chem       Date:  2020-01-08       Impact factor: 5.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.